Status:
COMPLETED
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
MALE
18-60 years
Phase:
PHASE1
Brief Summary
This is a study to assess the distribution, metabolism and excretion of \[14C\]AZD6765 after a single-dose intravenous administration.
Eligibility Criteria
Inclusion
- Subjects must have a normal creatinine clearance of ≥60 mL/min
- Subjects who self-identify their race as Asian
Exclusion
- History of any clinically significant medical, neurologic or psychiatric disease as judged by the investigator
- History of symptomatic orthostatic hypotension (ie, postural syncope)
- Subjects who have received any radiolabelled study drug within 12 months of the Screening Visit.
- Subjects who are monitored for radioactivity as part of their occupation
- Subjects who have been exposed to radiation levels above background, (eg, throughX-Ray examinations) of \>5mSv in the last year, \>10 mSv over the last 5 years or a cumulative total of \>1mSv per year of life.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01217645
Start Date
September 1 2010
End Date
October 1 2010
Last Update
October 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom